摘要
目的:提高对罕见的肺腺癌转变为肺鳞癌病理转变的认识。方法:报告1例靶向治疗后由肺腺癌转变为肺鳞癌的肺癌患者的临床诊疗经过,并结合文献进行复习。结果:老年女性患者,初诊为右肺上叶腺癌,给予吉非替尼治疗,无进展生存期9个月;随后出现疾病进展,进行二次肺活检,病理诊断为鳞癌;此后,患者因病情急剧恶化而死亡,无进展生存期不足2个月。结论:肺腺癌转变为肺鳞癌可能是对表皮生长因子-酪氨酸激酶抑制剂产生耐药的原因之一,需进一步探索其发生机制,有助于制定更加精准的治疗策略。
Objective:To improve the understanding of the rare pathological transformation from lung adenocarcinoma into squamous-cell carcinoma.Methods:The clinical diagnosis and treatment of a case of lung adenocarcinoma transformed into squamous-cell carcinoma after targeted therapy were reported,and the literatures were reviewed.Results:The elderly female patient treated with gefitinib due to adenocarcinoma in the right upper lobe of the lung achieved the progression-free survival(PFS)of 9 months.The second biopsy after disease progression showed that the pathological type of the lesion was squamous-cell carcinoma.The patient died after her condition deteriorated rapidly and the PFS was less than 2 months.Conclusion:The transformation of lung adenocarcinoma into squamous-cell carcinoma may be a cause of epidermal growth factor receptor-tyrosine kinase inhibitor(GFR-TKI)resistance.The mechanism needs to be further explored in order to make more accurate treatment strategies for such patients.
作者
王春伟
季现秀
谢惠康
罗洁
WANG Chunwei;JI Xianxiu;XIE Huikang;LUO Jie(Department of Respiratory and Critical Care Medicine,Dongchuan District People’s Hospital,Kunming 654100,Yunnan Province,China;Department of Oncology,Shanghai Pulmonary Hospital,Tongji University School of Medicine,Shanghai 200433,China;Department of Pathology,Shanghai Pulmonary Hospital,Tongji University School of Medicine,Shanghai 200433,China)
出处
《肿瘤》
CAS
CSCD
北大核心
2022年第12期830-834,共5页
Tumor
关键词
肺癌
腺癌
鳞癌
靶向治疗
病理转变
Lung cancer
Adenocarcinoma
Squamous-cell carcinoma
Targeted treatment
Pathological transformation
作者简介
Correspondence to:罗洁,E-mail:lj_1977@126.com
